Tilt Biotherapeutics

This clinical-stage biotechnology company develops immunotherapies for solid tumors using a patented oncolytic virus technology. The platform delivers viruses armed with cytokines, such as TNF and IL-2, to stimulate T-cell responses and convert immunologically cold tumors into hot ones. Their lead candidate, TILT-123, is designed for intravenous administration to target both primary and metastatic cancer cells.